Subscription results of rights offering or equity-linked bonds (voluntary)

A later amendment corrects this filing, so the terms on this page may be out of date. See the latest version (2026-08-12) →

What happened

Penetrium Bioscience / Subscription Results of Rights Offering or Equity-Linked Bonds, etc. (Voluntary Disclosure) / (2026.08.11) Subscription Results of Rights Offering or Equity-Linked Bonds, etc. (Voluntary Disclosure)

Subscription Results of Rights Offering or Equity-Linked Bonds, etc. (Voluntary Disclosure)

1. Type of security: Registered common stock 2. Issuance method: Rights offering (shareholder allotment) 3. Subscribers: General public offering subscribers (including subscriptions by high-risk high-return investment trusts and venture company investment trusts) 4. Subscription date: 2026-08-11 5. Subscription results - Planned number of shares to be issued: 8,500,000 - Relevant subscribed shares: 319,445,286 - Cumulative subscribed shares: 327,182,947 - Subscription rate (%): 3,849.21 6. Treatment of fractional shares and forfeited shares: - 7. Other matters material to investment decisions 1. The "4. Subscription date" above is the closing date of the general public offering subscription. (General public offering subscription period: August 10, 2026 to August 11, 2026) 2. Details of subscription results 2-1. Details of existing shareholders' subscription 1) Number of shares offered: 8,500,000 2) Number of shares subscribed under subscription warrants: 7,142,080 3) Number of oversubscribed shares: 595,581 (oversubscription allotment ratio: 100%) 4) Subscription rate: 91.03% 2-2. Details of general public offering subscription 1) Number of shares offered: 762,339 2) Shares subscribed by general investors: 308,642,218 (competition ratio: 674.77:1) 3) Shares subscribed by high-risk high-return investment trusts: 8,763,390 (competition ratio: 114.95:1) 4) Shares subscribed by venture company investment trusts: 2,039,678 (competition ratio: 8.92:1) 5) Total general subscription shares: 319,445,286 6) Subscription competition rate: 419.03% 3. The "planned number of shares to be issued" in item 5 "Subscription results" above is the total number of shares to be issued in this rights offering. 4. The "relevant subscribed shares" in item 5 "Subscription results" above is the number of shares subscribed in the general public offering. 5. The "cumulative subscribed shares" in item 5 "Subscription results" above is the simple sum of the existing shareholders' subscription and the general public offering subscription. 6. Future schedule 1) Refund and share-payment date: August 13, 2026 2) Scheduled listing date of new shares: August 28, 2026

Related disclosures: 2026-08-07 Subscription Results of Rights Offering or Equity-Linked Bonds, etc. (Voluntary Disclosure) 2026-08-03 Prospectus 2026-08-03 Securities Registration Statement (Equity Securities) 2026-08-03 Rights Offering Decision (Public Offering of Forfeited Shares after Shareholder Allotment) 2026-08-03 Rights Offering: Final Issue Price Set 2026-07-15 New Listing of Subscription Warrant Certificates (Penetrium Bioscience 10R) 2026-06-26 Prospectus 2026-06-26 Securities Registration Statement (Equity Securities) 2026-06-26 Rights Offering: First Issue Price Decision 2026-06-26 Rights Offering Decision (Public Offering of Forfeited Shares after Shareholder Allotment) 2026-06-11 Securities Registration Statement (Equity Securities) 2026-06-11 Rights Offering Decision (Public Offering of Forfeited Shares after Shareholder Allotment) 2026-05-27 Securities Registration Statement (Equity Securities) 2026-05-27 Rights Offering Decision (Public Offering of Forfeited Shares after Shareholder Allotment) 2026-04-30 Securities Registration Statement (Equity Securities) 2026-04-30 Rights Offering Decision (Public Offering of Forfeited Shares after Shareholder Allotment)